Spots Global Cancer Trial Database for mbc
Every month we try and update this database with for mbc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | NCT00434356 | Metastatic Brea... | bevacizumab sunitinib paclitaxel | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | NCT01745367 | Triple Negative... | Tivozanib Hydro... paclitaxel Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | NCT03315364 | Recurrent or Me... | Oral paclitaxel Paclitaxel inje... | 19 Years - | Daehwa Pharmaceutical Co., Ltd. | |
| Observation of Medical Treatments in MBC HER2-negative Patients | NCT02365831 | Metastatic Brea... | Observation of ... | 18 Years - | Consorzio Oncotech | |
| Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients | NCT02111031 | Metastatic Brea... Breast Cancer | 65 Years - | Janssen Diagnostics, LLC | ||
| A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) | NCT00281697 | Metastatic Brea... | Bevacizumab Placebo Standard chemot... | 18 Years - | Genentech, Inc. | |
| Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer | NCT00876070 | Metastatic Brea... | 18 Years - | SCRI Development Innovations, LLC | ||
| Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | NCT02238509 | Metastatic Brea... | Lapatinib Trastuzumab | 18 Years - | Consorzio Oncotech | |
| China CellSearch Study | NCT01116869 | Metastatic Brea... Benign Breast D... | 18 Years - 70 Years | Johnson & Johnson Medical, China | ||
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | NCT01160211 | Neoplasms, Brea... | lapatinib trastuzumab Aromatase inhib... lapatinib | 18 Years - | Novartis | |
| Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) | NCT00890903 | Non Small Cell ... Metastatic Brea... | 18 Years - | Pierre Fabre Pharma GmbH | ||
| Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer | NCT01978977 | Metastatic Brea... | 18 Years - | Hellenic Oncology Research Group | ||
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | NCT00679341 | Breast Cancer | Trastuzumab emt... Trastuzumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer | NCT00876070 | Metastatic Brea... | 18 Years - | SCRI Development Innovations, LLC | ||
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients | NCT02175446 | Metastatic Brea... Human Epidermal... | Bevacizumab and... | 18 Years - | Consorzio Oncotech | |
| Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients | NCT00428922 | Breast Cancer | Trastuzumab Bevacizumab Docetaxel | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments | NCT02284581 | Metastatic Brea... | 18 Years - | Consorzio Oncotech | ||
| A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer | NCT00679211 | Metastatic Brea... | Trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | NCT00509769 | Metastatic Brea... | Trastuzumab emt... | - | Genentech, Inc. | |
| Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments | NCT02284581 | Metastatic Brea... | 18 Years - | Consorzio Oncotech | ||
| Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) | NCT00890903 | Non Small Cell ... Metastatic Brea... | 18 Years - | Pierre Fabre Pharma GmbH | ||
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) | NCT02186015 | Adult Women Metastatic Brea... Estrogen Recept... | Cholecalciferol | 18 Years - | Loyola University | |
| Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients | NCT00428922 | Breast Cancer | Trastuzumab Bevacizumab Docetaxel | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer | NCT00876070 | Metastatic Brea... | 18 Years - | SCRI Development Innovations, LLC | ||
| Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression | NCT00943670 | Metastatic Brea... | pertuzumab Trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC | NCT04398108 | HER2 Positive M... | Margetuximab Ma... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Combination Study of SV-BR-1-GM With Retifanlimab | NCT03328026 | Breast Cancer Breast Neoplasm Metastatic Brea... Breast Cancer M... | SV-BR-1-GM Low dose cyclop... Interferon Inoc... retifanlimab | 18 Years - | BriaCell Therapeutics Corporation | |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | NCT06377852 | Metastatic Brea... | Palbociclib Ribociclib | 65 Years - | American Society of Clinical Oncology | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | NCT02223052 | Hematological N... Non-Hodgkin's L... Hodgkin's Lymph... Lymphoma Multiple Myelom... Acute Myeloid L... Leukemia Myelodysplastic... Neoplasms Melanoma Breast Cancer Metastatic Brea... Non-Small Cell ... Small Cell Lung... Renal Cell Carc... Glioblastoma Mu... Osteosarcoma Sarcoma Thyroid Cancer Genitourinary | CC-486 Vidaza | 18 Years - | Celgene | |
| Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | NCT00709618 | Neoplasms, Brea... | Lapatinib, Vino... | 18 Years - | GlaxoSmithKline | |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | NCT01745367 | Triple Negative... | Tivozanib Hydro... paclitaxel Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments | NCT02284581 | Metastatic Brea... | 18 Years - | Consorzio Oncotech | ||
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | NCT04965766 | Metastatic Brea... | U3-1402 | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen | NCT00932373 | Metastatic Brea... | trastuzumab-MCC... | - | Genentech, Inc. | |
| A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen | NCT00932373 | Metastatic Brea... | trastuzumab-MCC... | - | Genentech, Inc. | |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | NCT01745367 | Triple Negative... | Tivozanib Hydro... paclitaxel Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| China CellSearch Study | NCT01116869 | Metastatic Brea... Benign Breast D... | 18 Years - 70 Years | Johnson & Johnson Medical, China | ||
| A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | NCT00960960 | Breast Cancer | Bevacizumab Pictilisib Letrozole Paclitaxel Trastuzumab | 18 Years - | Genentech, Inc. | |
| Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments | NCT02284581 | Metastatic Brea... | 18 Years - | Consorzio Oncotech |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
